This is a specific type of lab test that uses radioactive materials to measure the amount of a particular protein or antibody in a sample. It's a very accurate way to count these substances.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
An immunoradiometric assay (IRMA) is a laboratory method for measuring very small amounts of a hormone or protein in a sample, usually blood. It relies on antibodies, immune proteins built to latch onto one specific target, and a small radioactive tag that lets the lab count how much of that target is present. The radioactive part stays in the laboratory: it is added to the sample in a test tube, and nothing radioactive goes into your body. You would not usually ask for an IRMA by name. Your clinician orders a particular test, such as thyroid-stimulating hormone, parathyroid hormone or thyroglobulin, and the lab decides which method to run it on. IRMA suits larger molecules like these. A common use is thyroglobulin monitoring after treatment for differentiated thyroid cancer, where a level that should be undetectable but is not prompts a closer look for remaining or returning disease. Many laboratories now run the same kind of two-antibody test with a light-producing label instead of a radioactive one. These non-radioactive versions are fully automated and faster, and for most people the choice of method makes no difference to what they experience.
Preparation depends on what is being measured rather than on the IRMA method. Most blood tests need no special preparation. Some require fasting for several hours, and some hormones change through the day or across the menstrual cycle, so the sample may need to be drawn at a set time. Your care team or the lab will tell you if any of this applies. Tell your clinician about every medicine and supplement you take, including high-dose biotin (often sold for hair, skin and nails), which can distort the results of some antibody-based tests. Do not stop a prescribed medicine unless your clinician tells you to.
For you, the procedure is an ordinary blood draw. A phlebotomist cleans the skin, places an elastic band around the upper arm and inserts a small needle into a vein, usually inside the elbow. Blood collects in a tube, and the whole draw typically takes less than five minutes. You may feel a brief sting as the needle goes in or out. The rest happens in the laboratory. Two different antibodies grab two different parts of the target molecule, sandwiching it between them. One antibody holds the complex in place; the other carries the radioactive tag. After unbound material is washed away, an instrument counts the remaining radioactivity. The more of the hormone or protein in your sample, the stronger the signal.
There is no recovery period. You can return to your usual activities right away. Some throbbing or a small bruise at the needle site is common and usually fades quickly. Your clinician interprets the result in light of your symptoms, other tests and any earlier results. Reference ranges differ between laboratories and methods, so tracking a level over time, such as thyroglobulin after thyroid cancer treatment, works best when the same lab and method are used each time. If a result does not fit how you are doing, the lab can recheck it, for example by diluting the sample or using a different method.
The physical risk is that of any blood draw: slight pain and bruising at the needle site, which usually go away quickly. The more meaningful risk is a misleading number. Antibodies in a person's own blood can interfere with the test's antibodies. Heterophile antibodies, which react with the animal proteins used in the test, usually push results falsely high and sometimes falsely low. They can occur in people who have received treatment with mouse-derived antibody drugs. High-dose biotin can interfere with tests that use biotin in their design. At extremely high concentrations, a sandwich test like IRMA can also underestimate the true level (the hook effect), which matters mainly for some tumors that make huge amounts of a hormone. For thyroglobulin, the main limitation is antithyroglobulin antibodies, which can make the result falsely low and hide disease. Guidelines therefore require these antibodies to be measured alongside every thyroglobulin test. When results and the clinical picture disagree, a method that does not use antibodies, such as mass spectrometry, may be used as a check.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Immunoradiometric Assay, what to expect, or ask the community a question.